Tags

Type your tag names separated by a space and hit enter

Factor analysis, including antihypertensive medication, of the outcome of pregnancy in pregnancy-associated hypertension.
Kidney Blood Press Res. 2001; 24(2):124-8.KB

Abstract

AIM

To study the influence of different maternal factors, including antihypertensive medication, on the outcome of pregnancy in primi- and multiparas with pregnancy-associated hypertension.

METHODS

A retrospective, multiple-variate analysis was undertaken of the influence of several maternal factors, including antihypertensive medication, on fetal death and Apgar scores and the correlation between the medication and the number of caesarean sections in 127 episodes of pregnancy-associated hypertension was studied for the whole group as well as for primi- and multiparas separately. Of the multiparas, 40.8% had a history of preeclampsia, 19.7% of chronic hypertension and 9.2% of diabetes mellitus. Antihypertensive treatment aimed at achieving a blood pressure of 140/90 mm Hg. Forty-one patients (32.3%) received intravenous hydralazine, 25 (19.7%) received nifedipine per os and 44 (34.6%) received labetalol per os.

RESULTS

The maximum systolic and diastolic blood pressure in the patients given intravenous hydralazine, nifedipine per os or labetalol per os did not differ, whereas in the multiparas, the number of patients who reached the target blood pressure while using labetalol was higher than with the two other medications, especially in comparison with intravenous hydralazine. For the primiparas, the time of delivery was the only factor with a significant impact on the Apgar scores. In the multiparas, there was an additional negative influence of the use of intravenous hydralazine. This was not seen in the patients using nifedipine and labetalol.

CONCLUSIONS

The results suggest that in multiparas, intravenous hydralazine is possibly associated with more fetal distress when compared to primiparas.

Links

FREE Publisher Full Text

Authors+Show Affiliations

Hussein M
Department of Nephrology, Dialysis and Hypertension, Al Hada Armed Forces Hospital, Taif, Saudi Arabia.
Mooij JM
No affiliation info available
Roujouleh H
No affiliation info available

MeSH

Antihypertensive AgentsApgar ScoreCesarean SectionComorbidityDisease SusceptibilityFemaleFetal DeathHumansHydralazineHypertensionInfant, NewbornLabetalolMultivariate AnalysisNifedipineParityPre-EclampsiaPregnancyPregnancy Complications, CardiovascularPregnancy OutcomePregnancy in DiabeticsRetrospective StudiesRisk Factors

Pub Type(s)

Journal Article

Language

eng

PubMed ID

11435745

Citation

Hussein, M, et al. "Factor Analysis, Including Antihypertensive Medication, of the Outcome of Pregnancy in Pregnancy-associated Hypertension." Kidney & Blood Pressure Research, vol. 24, no. 2, 2001, pp. 124-8.
Hussein M, Mooij JM, Roujouleh H. Factor analysis, including antihypertensive medication, of the outcome of pregnancy in pregnancy-associated hypertension. Kidney Blood Press Res. 2001;24(2):124-8.
Hussein, M., Mooij, J. M., & Roujouleh, H. (2001). Factor analysis, including antihypertensive medication, of the outcome of pregnancy in pregnancy-associated hypertension. Kidney & Blood Pressure Research, 24(2), 124-8.
Hussein M, Mooij JM, Roujouleh H. Factor Analysis, Including Antihypertensive Medication, of the Outcome of Pregnancy in Pregnancy-associated Hypertension. Kidney Blood Press Res. 2001;24(2):124-8. PubMed PMID: 11435745.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Factor analysis, including antihypertensive medication, of the outcome of pregnancy in pregnancy-associated hypertension. AU - Hussein,M, AU - Mooij,J M, AU - Roujouleh,H, PY - 2001/7/4/pubmed PY - 2001/10/26/medline PY - 2001/7/4/entrez SP - 124 EP - 8 JF - Kidney & blood pressure research JO - Kidney Blood Press Res VL - 24 IS - 2 N2 - AIM: To study the influence of different maternal factors, including antihypertensive medication, on the outcome of pregnancy in primi- and multiparas with pregnancy-associated hypertension. METHODS: A retrospective, multiple-variate analysis was undertaken of the influence of several maternal factors, including antihypertensive medication, on fetal death and Apgar scores and the correlation between the medication and the number of caesarean sections in 127 episodes of pregnancy-associated hypertension was studied for the whole group as well as for primi- and multiparas separately. Of the multiparas, 40.8% had a history of preeclampsia, 19.7% of chronic hypertension and 9.2% of diabetes mellitus. Antihypertensive treatment aimed at achieving a blood pressure of 140/90 mm Hg. Forty-one patients (32.3%) received intravenous hydralazine, 25 (19.7%) received nifedipine per os and 44 (34.6%) received labetalol per os. RESULTS: The maximum systolic and diastolic blood pressure in the patients given intravenous hydralazine, nifedipine per os or labetalol per os did not differ, whereas in the multiparas, the number of patients who reached the target blood pressure while using labetalol was higher than with the two other medications, especially in comparison with intravenous hydralazine. For the primiparas, the time of delivery was the only factor with a significant impact on the Apgar scores. In the multiparas, there was an additional negative influence of the use of intravenous hydralazine. This was not seen in the patients using nifedipine and labetalol. CONCLUSIONS: The results suggest that in multiparas, intravenous hydralazine is possibly associated with more fetal distress when compared to primiparas. SN - 1420-4096 UR - https://www.unboundmedicine.com/medline/citation/11435745/Factor_analysis_including_antihypertensive_medication_of_the_outcome_of_pregnancy_in_pregnancy_associated_hypertension_ L2 - https://www.karger.com?DOI=10.1159/000054218 DB - PRIME DP - Unbound Medicine ER -